Special populations and label expansion studies with the fixed dose combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique (ADAPT)

To progress with Phase 3b project as per agreement with EDCTP (WP1, WP3, WP4). To evaluate the peripheral parasitological clearance rate of P.falciparum malaria at day 42 in non-pregnant adults with malaria, taking either NVP-based or EFV-based antiretroviral drugs after administration of any of the three ACTs (AL, AS-AQ, DHA-PIPQ).